


# INTELLOTRACKER

## CAR T-Cell Therapy

May 2023



### ARANCA'S QUARTERLY SECTORIAL UPDATE ACROSS FOUR DIMENSIONS....





## DEVELOPMENTS

Product Launch		Eurofins Viracor ExPeCT™ CAR-T multiplexed quantitative real-time PCR (qPCR) assay provides a powerful diagnostic tool to monitor and optimize CAR-T therapy involving patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas. <i>Source: <a href="#">Company Website</a></i>
Technology/Innovations		Recent study published in Nature showed that certain components of human gut microbiome could be used as biomarkers to better predict the efficacy of CAR-T cell therapy using machine learning. <i>Source: <a href="#">Nature</a></i>
Technology/Innovations		A research group from the Chinese Academy of Sciences has developed a CAR T cell-based microrobot (M-CAR T) with magnetic-acoustic sequential actuation that can autonomously navigate to tumor sites for cell immunotherapy. <i>Source: <a href="#">Wiley</a></i>
Technology/Innovations		University Hospital Erlangen in Germany is the first in the world to use chimeric antigen receptor (CAR) T-cells to successfully treat a patient suffering from a severe case of muscle inflammation (myositis). <i>Source: <a href="#">European Pharma</a></i>
Technology/Innovations		A preclinical study from researchers at the Perelman School of Medicine at the University of Pennsylvania suggests that CAR T cell therapy may also improve the outcomes of surgical treatment for solid tumors. <i>Source: <a href="#">Science Advances</a></i>



## DRIVERS




Regulation/Approvals		The U.S. FDA has granted both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation to its investigational new drug BCMA CAR-T CT103A (Equecabtagene Autoleucl) for relapsed/refractory multiple myeloma. <i>Source: <a href="#">Company Website</a></i>
Regulation/Approvals		Jaypirca has been approved under the FDA's Accelerated Approval pathway for adult patients with relapsed or refractory mantle cell lymphoma based on response rate from the open-label, international, Phase 1/2 study, called the BRUIN trial. <i>Source: <a href="#">Company Website</a></i>
Regulation/Approvals		The U.S. FDA has cleared the Sana Biotechnology's Investigational New Drug (IND) application to initiate a first-in-human study of SC291 in patients with various B-cell malignancies. <i>Source: <a href="#">Globe Newswire</a></i>
Regulation/Approvals		The U.S. FDA has cleared an investigational new drug (IND) application for the bispecific autologous CAR T-cell therapy, IMPT-314, for the treatment of patients with aggressive B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL). <i>Source: <a href="#">PR Newswire</a></i>
Regulation/Approvals		FDA has given the "safe to proceed" letter for Carina Biotech's Investigational New Drug (NDA) application to conduct a first-in-human clinical trial of CNA3103, its LGR5-targeted CAR T therapy candidate, in patients with advanced colorectal cancer. <i>Source: <a href="#">BioSpace</a></i>



## DIVERSIFICATION

Investment		CARGO Therapeutics has raised \$200 Million in oversubscribed, upsized series A financing to advance CARGO's autologous CD22 CAR T-cell therapy candidate, CRG-022, through a pivotal multicenter Phase 2 trial. <i>Source: <a href="#">Company Website</a></i>
Investment		MPC Therapeutics, a Swiss biotechnology company focused on metabolism and rejuvenation, announced the closing of its CHF 1.5 million seed-funding round. Their lead program aims to improve the performance and durability of CAR-T therapy. <i>Source: <a href="#">Business Wire</a></i>
Collaboration		This research and process development-focused collaboration has enabled ArsenalBio to develop a robust manufacturing process for their next-generation, programmable autologous T cells for the treatment of cancer. <i>Source: <a href="#">Company Website</a></i>
Collaboration		In a first-of-its-kind commercial agreement, Great Ormond Street Hospital NHS Foundation Trust (GOSH) will work with Leucid Bio to manufacture LEU011, a lateral Chimeric Antigen Receptor (CAR) targeting NKG2D ligands. <i>Source: <a href="#">GOSH</a></i>
Collaboration		Danaher has partnered with the University of Pennsylvania to develop technologies for improving the consistency of clinical outcomes for patients and overcome manufacturing bottlenecks in the delivery of next generation engineered cell products. <i>Source: <a href="#">Company Website</a></i>
Collaboration		Nexcella has entered into a manufacturing agreement with a well-known U.S. GMP cell therapy manufacturer that will supply a US Phase 1b/2 clinical trial of NXC-201 in relapsed/refractory multiple myeloma and AL amyloidosis. <i>Source: <a href="#">Globe Newswire</a></i>

## SOLUTION PORTFOLIO – TECHNOLOGY RESEARCH & ADVISORY

		
IP Strategy	Technology Intelligence	Growth & Strategy
<p>How best can we proactively manage and monetise our technical knowhow / intellectual property?</p>	<p>How best can we keep abreast of technology trends, competitor activity and headwinds / tailwinds in our domain?</p>	<p>Which technologies do we invest in? How do we ensure quick wins? Speed to market?</p>
<ul style="list-style-type: none"> <li>IP Portfolio Analysis</li> </ul>	<ul style="list-style-type: none"> <li>Competitor Benchmarking</li> </ul>	<ul style="list-style-type: none"> <li>R&amp;D Strategy Roadmaps</li> </ul>
<ul style="list-style-type: none"> <li>IP Monetisation</li> </ul>	<ul style="list-style-type: none"> <li>Tech / IP Landscapes</li> </ul>	<ul style="list-style-type: none"> <li>Technology Scouting</li> </ul>
<ul style="list-style-type: none"> <li>IP Valuation</li> </ul>	<ul style="list-style-type: none"> <li>Technology Watch</li> </ul>	<ul style="list-style-type: none"> <li>Open Innovation</li> </ul>
<ul style="list-style-type: none"> <li>Prior Art Searches</li> </ul>	<ul style="list-style-type: none"> <li>Market Analysis / Trends</li> </ul>	<ul style="list-style-type: none"> <li>Product Development</li> </ul>



GROWTH  
ADVISORY



INVESTMENT  
RESEARCH  
& ANALYTICS



VALUATION  
& FINANCIAL  
ADVISORY



TECHNOLOGY  
RESEARCH  
& ADVISORY



PROCUREMENT &  
SUPPLY CHAIN  
INTELLIGENCE

This material is exclusive property of Aranca. No part of this presentation may be used, shared, modified and/or disseminated without permission. All rights reserved.